Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review
- PMID: 21466501
- PMCID: PMC3154701
- DOI: 10.2174/1874473711104010028
Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review
Abstract
The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world. We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
From research to the real world: buprenorphine in the decade of the Clinical Trials Network.J Subst Abuse Treat. 2010 Jun;38 Suppl 1(Suppl 1):S53-60. doi: 10.1016/j.jsat.2010.01.009. J Subst Abuse Treat. 2010. PMID: 20307796 Free PMC article.
-
The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Expert Opin Pharmacother. 2009. PMID: 19708849 Review.
-
Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.J Opioid Manag. 2013 Jul-Aug;9(4):237. J Opioid Manag. 2013. PMID: 24380101 No abstract available.
-
Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?J Addict Med. 2012 Sep;6(3):179-85. doi: 10.1097/ADM.0b013e318257377f. J Addict Med. 2012. PMID: 22614935 Free PMC article.
-
Buprenorphine and naloxone for heroin dependence.Curr Psychiatry Rep. 2000 Dec;2(6):519-26. doi: 10.1007/s11920-000-0012-8. Curr Psychiatry Rep. 2000. PMID: 11123005 Review.
Cited by
-
Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.J Subst Use Addict Treat. 2023 Apr;147:208973. doi: 10.1016/j.josat.2023.208973. Epub 2023 Feb 10. J Subst Use Addict Treat. 2023. PMID: 36804351 Free PMC article.
-
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.Drugs. 2018 Aug;78(12):1211-1228. doi: 10.1007/s40265-018-0953-z. Drugs. 2018. PMID: 30051169 Free PMC article. Review.
-
Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?Subst Abus. 2019;40(2):148-153. doi: 10.1080/08897077.2019.1572052. Epub 2019 Apr 22. Subst Abus. 2019. PMID: 31008694 Free PMC article.
-
Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.Subst Abuse Treat Prev Policy. 2017 Nov 2;12(1):46. doi: 10.1186/s13011-017-0131-4. Subst Abuse Treat Prev Policy. 2017. PMID: 29096661 Free PMC article.
-
Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.Drug Alcohol Depend. 2017 Oct 1;179:362-369. doi: 10.1016/j.drugalcdep.2017.06.033. Epub 2017 Jul 26. Drug Alcohol Depend. 2017. PMID: 28844013 Free PMC article.
References
-
- United Nations Office on Drugs and Crime. World Drug Report. 2007.
-
- World Health Organization. WHO Drug Information. 3. Vol. 19. 2005. p. 72.
-
- World Health Organization, Office on Drugs and Crime. Drug Report. 2007.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical